CN117730083A - 用作map4k1抑制剂的嘧啶化合物 - Google Patents

用作map4k1抑制剂的嘧啶化合物 Download PDF

Info

Publication number
CN117730083A
CN117730083A CN202280048104.2A CN202280048104A CN117730083A CN 117730083 A CN117730083 A CN 117730083A CN 202280048104 A CN202280048104 A CN 202280048104A CN 117730083 A CN117730083 A CN 117730083A
Authority
CN
China
Prior art keywords
amino
methoxy
chloro
pyrimidin
tetrahydroisoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280048104.2A
Other languages
English (en)
Chinese (zh)
Inventor
普拉文·艾耶尔
桑吉布·达斯
穆鲁干·钦纳帕图
萨钦·乔杜哈里
贾格莫汉·赛尼
斯拉万·曼达迪
纳加拉吉·戈达
德尼亚内什瓦尔·达哈勒
桑迪普·帕蒂尔
纳纳萨赫布·卡德拉格
钱德拉塞卡·米斯拉
普里扬卡·潘加雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Specialty SA
Original Assignee
Glenmark Specialty SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Specialty SA filed Critical Glenmark Specialty SA
Publication of CN117730083A publication Critical patent/CN117730083A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280048104.2A 2021-07-06 2022-07-06 用作map4k1抑制剂的嘧啶化合物 Pending CN117730083A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121030204 2021-07-06
IN202121030204 2021-07-06
PCT/IB2022/056248 WO2023281417A1 (en) 2021-07-06 2022-07-06 Pyrimidine compounds for use as map4k1 inhibitors

Publications (1)

Publication Number Publication Date
CN117730083A true CN117730083A (zh) 2024-03-19

Family

ID=82703212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280048104.2A Pending CN117730083A (zh) 2021-07-06 2022-07-06 用作map4k1抑制剂的嘧啶化合物

Country Status (14)

Country Link
US (1) US12577267B2 (https=)
EP (1) EP4367123A1 (https=)
JP (1) JP2024527565A (https=)
KR (1) KR20240012538A (https=)
CN (1) CN117730083A (https=)
AU (1) AU2022305807B2 (https=)
CA (1) CA3223874A1 (https=)
CL (1) CL2023003791A1 (https=)
CO (1) CO2024000572A2 (https=)
EC (1) ECSP24007193A (https=)
IL (1) IL309342A (https=)
MX (1) MX2023015246A (https=)
PE (1) PE20240585A1 (https=)
WO (1) WO2023281417A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231875A1 (en) 2023-05-09 2024-11-14 Glenmark Specialty S.A. Hpk1 inhibitor for use in the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2792979T3 (es) * 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
WO2018102366A1 (en) * 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
AU2020406824A1 (en) * 2019-12-16 2022-08-11 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative and use thereof

Also Published As

Publication number Publication date
AU2022305807A1 (en) 2024-01-04
AU2022305807B2 (en) 2024-09-05
JP2024527565A (ja) 2024-07-25
US20230227483A1 (en) 2023-07-20
MX2023015246A (es) 2024-01-19
US12577267B2 (en) 2026-03-17
WO2023281417A1 (en) 2023-01-12
CA3223874A1 (en) 2023-01-12
PE20240585A1 (es) 2024-03-21
CL2023003791A1 (es) 2024-07-12
CO2024000572A2 (es) 2024-02-05
IL309342A (en) 2024-02-01
KR20240012538A (ko) 2024-01-29
ECSP24007193A (es) 2024-03-01
EP4367123A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US10807982B2 (en) Bromodomain inhibitors
US9255089B2 (en) Benzimidazolone derivatives as bromodomain inhibitors
CN112601752A (zh) Map4k1的新颖抑制剂
CN108026102A (zh) 可用于治疗与kit和pdgfr相关的病症的化合物
CN115703775A (zh) 一种kras突变体g12c抑制剂及其制备方法和应用
JP7101311B2 (ja) Ｍａｐ４ｋ１阻害剤として使用するためのインドリノン化合物
TW201506028A (zh) １，２-雙取代雜環化合物
JP7678929B2 (ja) ピリジノンｍｋ２阻害剤及びその使用
HK1210608A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
WO2013170774A1 (zh) 具有抗肿瘤活性的乙炔衍生物
WO2022199662A1 (zh) 一种多环化合物及其应用
TWI553011B (zh) 雜芳族化合物以及其作為多巴胺ｄ１配體的用途
WO2016011979A1 (zh) 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
WO2022272106A1 (en) Cdk2 inhibitors and methods of using the same
TW202515544A (zh) 作為ｃ－ｋｉｔ激酶抑制劑的醫藥化合物及組合物
KR20230104782A (ko) Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물
JP7233130B2 (ja) Ｉｒａｋ４阻害剤としての新規な三環式化合物
CN119451964A (zh) Fgfr2和fgfr3抑制剂及其用途
CN113461670A (zh) 作为转染期间重排激酶抑制剂的新的化合物
CN113461687B (zh) 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
CN117730083A (zh) 用作map4k1抑制剂的嘧啶化合物
CN115433184A (zh) Hpk1抑制剂及其应用
EA048523B1 (ru) Пиримидиновые соединения для применения в качестве ингибиторов map4k1
OA21470A (en) Pyrimidine compounds for use as MAP4K1 inhibitors.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination